Press Releases
leaf

Press Releases

Press releases

Jun 9, 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy

Jun 8, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy

Jun 1, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy

May 28, 2020
Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis

May 18, 2020
Akcea Announces Appointment of New Chief Financial Officer

May 14, 2020
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

May 13, 2020
Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection)

May 7, 2020
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer

May 5, 2020
Akcea Reports Financial Results and Highlights for First Quarter 2020

Apr 21, 2020
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast

Mar 24, 2020
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO

Mar 11, 2020
Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team

Feb 28, 2020
Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”

Feb 26, 2020
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference

Feb 25, 2020
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019

Feb 18, 2020
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast

Feb 13, 2020
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman

Jan 28, 2020
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

Jan 10, 2020
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

Jan 2, 2020
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

Dec 18, 2019
Akcea Retains Rights to AKCEA-APOCIII-LRx

Dec 16, 2019
Akcea Therapeutics Announces New Appointments to its Board of Directors

Dec 4, 2019
Akcea Announces Appointment of New Chief Operating Officer

Nov 25, 2019
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

Nov 19, 2019
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

Nov 13, 2019
Akcea Therapeutics to Present at Upcoming Investor Conferences

Nov 5, 2019
Akcea Reports Financial Results and Highlights for Third Quarter 2019

Nov 1, 2019
Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day

Oct 23, 2019
Akcea Announces Appointment of New Chief Commercial Officer

Oct 22, 2019
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast

Oct 7, 2019
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

Sep 23, 2019
Akcea Announces CEO Transition and Elects Two New Board Members

Sep 16, 2019
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

Aug 29, 2019
Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

Aug 7, 2019
New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome

Aug 6, 2019
Akcea Reports Financial Results and Highlights for Second Quarter 2019

Aug 6, 2019
Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy

Jul 29, 2019
Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast

Jul 16, 2019
hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch

Jun 26, 2019
Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress

Jun 20, 2019
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting

May 28, 2019
Akcea Therapeutics to Present at Upcoming Investor Conferences

May 8, 2019
Akcea Reports Financial Results and Highlights for First Quarter 2019

May 7, 2019
Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union

May 7, 2019
New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

May 2, 2019
Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)

Apr 24, 2019
Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast

Mar 15, 2019
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

Mar 1, 2019
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™ (volanesorsen)

Feb 28, 2019
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

Feb 26, 2019
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018

Feb 25, 2019
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

Feb 20, 2019
Akcea Therapeutics to Present at Upcoming Investor Conferences

Feb 13, 2019
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

Nov 29, 2018
Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

Nov 12, 2018
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

Nov 8, 2018
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions

Nov 6, 2018
Akcea Therapeutics to Present at Upcoming Investor Conferences

Nov 5, 2018
Akcea Reports Financial Results and Highlights for Third Quarter 2018

Nov 2, 2018
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day

Oct 22, 2018
Akcea Therapeutics to Hold Third Quarter 2018 Financial Results Webcast

Oct 8, 2018
Akcea Announces Changes to Board of Directors

Oct 5, 2018
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Oct 5, 2018
Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)

Oct 4, 2018
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada

Sep 24, 2018
Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

Aug 29, 2018
Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference

Aug 27, 2018
Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

Aug 6, 2018
Akcea Reports Financial Results and Highlights for Second Quarter 2018

Aug 2, 2018
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

Jul 31, 2018
Akcea Announces Publication of Study Results Showing Multiple Benefits of Patient-to-Patient Connectivity in FCS

Jul 23, 2018
Akcea Therapeutics to Hold Second Quarter 2018 Financial Results Webcast

Jul 11, 2018
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

Jul 5, 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

Jun 13, 2018
Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

Jun 12, 2018
Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis

Jun 5, 2018
Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors

Jun 1, 2018
Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

May 29, 2018
Akcea Therapeutics to Present at the Jefferies Global Healthcare Conference

May 10, 2018
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome

May 3, 2018
Akcea Reports Financial Results and Highlights for First Quarter 2018

May 2, 2018
Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS

Apr 26, 2018
Akcea Therapeutics to Hold First Quarter 2018 Financial Results Webcast

Apr 26, 2018
Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions

Apr 21, 2018
Akcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 American Academy of Neurology Annual Meeting

Apr 17, 2018
Sarah Boyce Joins Akcea Therapeutics as President and Member of the Board of Directors

Apr 17, 2018
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR

Mar 26, 2018
Akcea Convenes First FCS Global Connection Summit

Mar 26, 2018
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis

Mar 21, 2018
MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)

Mar 15, 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR

Mar 12, 2018
Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo

Mar 6, 2018
Akcea Therapeutics to Present at Upcoming Investor Conferences

Feb 28, 2018
Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic “Firsts” for People Living with Familial Chylomicronemia Syndrome

Feb 27, 2018
Akcea Therapeutics Canada Announces the Launch of FCS Focus Education & Support Program

Feb 26, 2018
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017

Feb 15, 2018
Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome

Feb 12, 2018
Akcea Therapeutics to Hold Fourth Quarter 2017 Financial Results Webcast

Feb 7, 2018
Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx

Jan 5, 2018
Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease

Dec 14, 2017
Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)

Dec 7, 2017
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Nov 15, 2017
Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS

Nov 13, 2017
Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias

Nov 7, 2017
Akcea to Present at Stifel 2017 Healthcare Conference

Nov 6, 2017
Akcea Reports Financial Results and Highlights for Third Quarter 2017

Oct 31, 2017
Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx

Oct 27, 2017
Akcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts for Second Consecutive Year

Oct 23, 2017
Akcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast

Oct 16, 2017
Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome

Oct 10, 2017
Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)

Oct 4, 2017
Akcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical Director

Sep 12, 2017
Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada

Sep 12, 2017
Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada

Sep 6, 2017
Akcea Therapeutics Establishes Canadian Subsidiary

Sep 5, 2017
Akcea Expands Leadership Team in Preparation for First Commercial Launch

Aug 31, 2017
Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA

Aug 29, 2017
Akcea to Present at Wells Fargo Healthcare Conference

Aug 8, 2017
Akcea Reports Financial Results and Highlights for Second Quarter 2017

Jul 27, 2017
Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency

Jul 19, 2017
Akcea Therapeutics Announces Closing of Initial Public Offering

Jul 13, 2017
Akcea Therapeutics Announces Pricing of Initial Public Offering

Jun 27, 2017
Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes

Jun 20, 2017
Akcea Therapeutics Launches Proposed Initial Public Offering

May 25, 2017
Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-LRx Showing Favorable Cardiometabolic Effects

May 9, 2017
Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors

Mar 30, 2017
Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease

Mar 28, 2017
Akcea Therapeutics Announces Three Additions to Board of Directors

Mar 27, 2017
Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering

Mar 6, 2017
Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)

Feb 16, 2017
Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx

Jan 6, 2017
Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx

Dec 21, 2016
Carousel Display of Mulitple Assets

Dec 21, 2016
Gallery Display of Many Assets

Dec 21, 2016
Inline with Assets

Dec 19, 2016
Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen

Nov 15, 2016
Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-LRx

Sep 22, 2016
Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease

Sep 15, 2016
Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome

Jul 28, 2016
Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)

Jun 29, 2016
Akcea Therapeutics Announces Launch of IN-FOCUS, a Research Study to Assess Impact of Familial Chylomicronemia Syndrome

May 16, 2016
Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen

Apr 6, 2016
Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference

Mar 31, 2016
Akcea Therapeutics Supports World Lipodystrophy Day

Mar 4, 2016
Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

Jan 19, 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer

Nov 8, 2015
Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs

Nov 5, 2015
Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Jul 29, 2015
Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine

Jul 22, 2015
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

Jul 6, 2015
Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome

May 28, 2015
Webcast Alert: Akcea Therapeutics Conference Call

Jun 24, 2013
Mulitple Assets in a News Release

Mar 1, 2011
TEST RELEASE with wide tables

Nov 6, 2007
News Release Headline

Nov 5, 2007
News Release Headline

Supporting patients

Discover the ways in which Akcea Canada supports patients and Healthcare Professionals alike.

Inside Akcea

Learn about the Akcea mindset.